Table 3.
Burden of DPR and aDMA by region in clinicopathologic subgroups
| FCtx | DF | CA4 | CA2/3 | MCtx | |
|---|---|---|---|---|---|
| poly-GA | |||||
| FTLD | 6.4 (3.8, 9.4) | 310 (110, 470) | 6 (4.1, 9.5) | 5.6 (4.5, 8.3) | 5.8 (3.7, 12) |
| FTLD-MND | 7.5 (5.6, 15) | 420 (320, 630) | 9.5 (6.6, 13) | 9.7 (4.7, 15) | 14 (6.2, 17) |
| MND | 7.4 (5.8, 13) | 380 (280, 480) | 10 (7.4, 14) | 8.2 (3.0, 12) | 9.3 (6.5, 13) |
| poly-GP | |||||
| FTLD | 9.7 (5.9,14) | 120 (71, 262) | 8 (6.7, 13) | 19 (13, 33) | 10 (6.7, 13) |
| FTLD-MND | 13 (11, 18) | 180 (98, 270) | 13 (7.4, 18) | 31 (19, 39) | 10 (8.0, 14) |
| MND | 10 (6.6, 16) | 130 (86, 230) | 13 (10, 17) | 27 (16, 39) | 11 (4.9, 18) |
| poly-GR | |||||
| FTLD | 3.0 (2.2, 4.2) | 16 (9.5, 48) | 3.0 (2.3, 5.6) | 5.1 (3.3, 9.3) | 2.6 (1.3, 5.5) |
| FTLD-MND | 6.8 (3.7, 9.5)* | 49 (26, 86)* | 8.5 (6.8, 12)* | 17 (11, 26)* | 4.7 (3.1, 7.9) |
| MND | 2.9(1.1, 3.4) | 26 (18, 51) | 7.5 (4.7, 8.8) | 12 (3.7, 22) | 2.6 (1.2, 4.9) |
| aDMA | |||||
| FTLD | 3.3 (2.8, 4.7) | 83 (31, 100) | 10 (6.8, 14) | 16 (10, 37) | 3.4 (2.1, 5.6) |
| FTLD-MND | 5.5 (3.1, 8.2) | 77 (21, 140) | 17 (14, 22)* | 25 (17, 36) | 5.6 (4.6, 6.8) |
| MND | 4.0 (2.1, 7.4) | 53 (31, 81) | 15 (12, 20) | 15 (6, 29) | 3.5(2.5, 5.6) |
In frontal cortex, p < 0.001, FTLD vs. FTLD-MND, p = 0.005, FTLD-MND v.s MND. In DF, p = 0.02, FTLD vs. FTLD-MND. In CA4, p = 0.002, FTLD vs. FTLD-MND. In CA2/3, p = 0.003, FTLD vs. FTLD-MND. All variables analyzed with Kruskal-Wallis ANOVA on Ranks and data are displayed as median (25th and 75th range)
*Statistically significant p-value (p < 0.05); all p-value for ANOVA on Ranks comparison of all three groups
FCtx frontal cortex, MCtx Motor cortex, DF dentate fascia, CA (cornu ammonis)